Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phosphate-lowering efficacy of different doses of SBR759 vs placebo in CKD patients on renal replacement therapy
2008-006097-15Phase 3Terminated
- Sponsor
- Novartis
- Start
- Mar 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SBR759 in hyperphosphatemia and chronic kidney disease (CKD) (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in 72-hour serum phosphate at 4 weeks. Started Mar 2009; status: terminated.
02
Drugs
SBR759
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2008-006097-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006097-15.